TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2016 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Executive Vice President and Chief Business Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 at 9:20 AM Eastern Standard Time.
The live webcast will be accessible at http://investor.fiveprime.com/events.cfm or directly at http://wsw.com/webcast/leerink26/fprx. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe, Investor Relations 415-365-5737 [email protected]
